Postprandial Glucose

Postprandial Glucose

Postprandial glucose refers to the concentration of glucose in the blood during the period following food intake, typically measured at one or two hours after the start of a meal. In healthy individuals, postprandial glucose levels rarely exceed 7.8 mmol/L (140 mg/dL) due to the coordinated actions of insulin secretion, hepatic glucose uptake, and peripheral glucose disposal. In individuals with impaired glucose tolerance or type 2 diabetes, these regulatory mechanisms are compromised, leading to exaggerated and prolonged postprandial glucose excursions that contribute to overall glycemic burden as reflected by elevated hemoglobin A1c levels.

Postprandial hyperglycemia is increasingly recognized as an independent risk factor for cardiovascular disease, even in the absence of fasting hyperglycemia. Elevated glucose levels after meals promote oxidative stress, endothelial dysfunction, and advanced glycation end-product formation, all of which accelerate atherosclerotic processes. Consequently, therapeutic strategies that specifically target postprandial glucose control — including incretin-based therapies, alpha-glucosidase inhibitors, and rapid-acting insulin analogs — have gained importance in comprehensive diabetes management. The incretin hormones GLP-1 and GIP are particularly effective at reducing postprandial glucose because their secretion is physiologically linked to nutrient ingestion.

Clinical Relevance to Retatrutide

Retatrutide addresses postprandial glucose elevations through multiple complementary mechanisms. GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release from alpha cells, and slows gastric emptying to moderate the rate of nutrient absorption. GIP receptor agonism further potentiates the insulin secretory response to meals. In clinical trials involving participants with type 2 diabetes, retatrutide produced significant reductions in postprandial glucose excursions alongside improvements in fasting glucose and hemoglobin A1c, consistent with its multi-receptor pharmacological profile addressing both the incretin deficit and broader metabolic dysregulation characteristic of the disease.